Introduction
============

Lung cancer remains the most common cause of cancer-related mortality worldwide.[@b1-cmar-11-1945] Non-small-cell lung cancer (NSCLC) accounts for \~85% of lung cancer.[@b2-cmar-11-1945] Adenocarcinoma (ADC) and squamous cell carcinoma (SCC) are two major histological subtypes of NSCLC. Although conventional treatment strategies including surgery, chemotherapy, and radiotherapy have improved the prognosis of NSCLC patients, the side effects on life quality should not be ignored. In the past few decades, studies on signaling pathways involved in the onset and progression of NSCLC have acquired great achievements, especially the ectopic activation of *EGFR* which plays a crucial role in the tumor growth and invasiveness. About 40% of NSCLC patients presented the dysregulation of *EGFR*.[@b3-cmar-11-1945] The somatic mutations of *EGFR* prominently locate in the exons 19--23, which encode the tyrosine kinase domain.[@b4-cmar-11-1945] Approximately 70% of Asian female nonsmoker patients with ADC harbored *EGFR* mutations.[@b5-cmar-11-1945] Exon 19 deletions (19-del) and exon 21 missense mutation (L858R) are the two predominant mutant subtypes of *EGFR* in NSCLC. Tyrosine kinase inhibitors (TKIs), which specifically target *EGFR* mutations (19-del and L858R), could improve the prognosis of NSCLC patients harboring *EGFR* mutations, and have been recommended as the first-line therapy in lung cancer patients with *EGFR* mutations.[@b6-cmar-11-1945] Some recent studies presented that patients harboring 19-del had a better overall survival compared with those with L858R following TKIs treatment especially in advanced-stage NSCLC, while others failed to reach this conclusion.[@b7-cmar-11-1945]--[@b10-cmar-11-1945] As a result, the difference of 19-del and L858R in the prognosis of patients harboring *EGFR* mutations remains controversial.

The condition that tumors adjacent to the pleural might be an unfavorable prognostic factor was first observed by Brewer et al in 1958.[@b11-cmar-11-1945] Compared with tumors growing in the mid-lung zone, tumors under pleural surface had an adverse influence on survival. Since that, visceral pleural invasion (VPI) has been identified as an adverse factor for the survival of patients who underwent NSCLC resection.[@b12-cmar-11-1945] In the eighth edition of AJCC TNM classification for lung cancer, VPI was an essential factor for the T descriptors -- tumors ≤3cm will be upstaged to T2 stage if they invade the visceral pleural.[@b13-cmar-11-1945]

According to the previous researches, tumors with VPI presented more aggressive invasiveness, which may lead to the dissemination of tumor cells in the pleural cavity and mediastinal lymph node metastasis.[@b14-cmar-11-1945] A great number of studies have focused on the prognostic value of VPI stratified by the tumor size, especially the necessity of chemotherapy for postoperative patients with VPI in early stage NSCLC.[@b12-cmar-11-1945],[@b15-cmar-11-1945],[@b16-cmar-11-1945] Computer tomography (CT) is an important imaging method in diagnosis of NSCLC. Three types of tumor--pleural relationship could be observed on CT images including no contacting, abutting pleural, and pleural tag. Some studies suggested that tumors abutting the pleural surface can predict 77% of VPI in accuracy.[@b17-cmar-11-1945] Pleural tag, which represents the stripes stretching from the tumor margin to the pleural surface, is formed from thickened interlobular septa. This important CT feature could be classified into three types (pleural tag type I, type II, and type III) according to Hsu et al's study. Tumors with pleural tags may be an important clue to prejudge VPI, and the positive predictive value is up to 76.2% according to different types observed on CT images.[@b18-cmar-11-1945] Although it is commonly recognized that tumors that contact the pleural presented on CT scans have large potential of VPI, it is still difficult to diagnose VPI from CT images accurately.

Numerous researches focused on the prognostic value of VPI stratified by tumor size, while limited studies shed light on the correlation of *EGFR* mutations and VPI. In order to clarify their relationship in NSCLC, a retrospective study was conducted to investigate the association between *EGFR* mutations and VPI, and evaluate their prognostic value in NSCLC patients who underwent primary tumor resection.

Materials and methods
=====================

Patient selection and follow-up
-------------------------------

Seven hundred eleven consecutive patients who underwent primary tumor lobectomy and *EGFR* mutation detection were included in our current study to analyze the association between *EGFR* mutations and VPI as well as their roles in the prognosis of NSCLC patients in Shanghai Pulmonary Hospital from November 2013 to May 2014. The exclusion criteria were 1) pathological stage IV diagnosed after surgery,2) administration of preoperative chemotherapy, radiation therapy, or EGFR-TKIs; 3) patients who died of surgical complications in perioperative period. Written informed consent was obtained from all patients before surgery, and the study was approved by the Review Board of Shanghai Pulmonary Hospital. This study was conducted in accordance with the Declaration of Helsinki. Finally, 508 patients with resected NSCLC were included in this study; clinicopathologic characteristics including gender, age, smoking status, tumor size, histological type, preoperative carcinoembryonic antigen (CEA) level, pathological TNM (pTNM) stage, and postoperative therapy were collected. Pathologic staging was performed according to the eighth edition of TNM classification.

Each patient received regular follow-up mainly in outpatient department or by telephone, and latest examination reports were recorded for rechecking. Consultant doctors checked radiological images of all patients who visited our outpatient department for postoperative follow-up and compared with the former ones. The examination reports for these patients were recorded in our hospital health system. For a minority of patients living far away, they would choose to be followed in the local hospital, and we would keep in touch with them by telephone every 3 months and enquired about their examination reports then recorded. For these patients, we checked their radiological reports instead. The disease-free survival (DFS) was defined as the time from the day of operation to the day of confirmation of recurrence according to clinical and radiological findings.

CT imaging, pathologic diagnosis, and EGFR mutation analysis
------------------------------------------------------------

All patients underwent chest CT in our hospital within 1 month before surgery. CT images were performed using CT scanner systems (SIEMENS Somatom Definition AS; Siemens Medical Systems, Erlangen, Germany) according to the parameters as follows: section width, 2.0 mm; reconstruction interval, 1.0 mm; slice acquisition, 128×0.6 mm; rotation time, 0.5 seconds; tube voltage, 120 kVp; tube current, 300 mA. CT images were assessed by two experienced radiologists using standard lung (window width, 1,600 HU; window level, −600 HU) and mediastinal (window width, 350 HU; window level, 50 HU) window settings. The relationship of tumor and pleural on CT scans was recorded for each patient. For tumors showing pleural tags on lung window, we classified them into three types as previously reported by Hsu et al.[@b18-cmar-11-1945] Surgical specimens were reviewed by two experienced pathologists. For *EGFR* mutation analysis, genomic DNA was extracted from fresh tissues using QIAamp DNA Tissue Kit (Qiagen, Hilden, Germany). Mutations of *EGFR* were detected using commercially available kits from ACCB Diagnostics (Beijing, China). The procedure was based on amplification refractory mutation system real-time PCR technology. All experiments were performed according to the manufacturer's instructions.

Statistical analysis
--------------------

The differences in distribution of categorical variables were assessed by Pearson's chi-squared test or the Fisher's exact test. Independent *t*-test was carried out to evaluate the difference of mean value for continuous variables. Univariate logistic regression was performed to investigate the association between clinicopathologic characteristics and VPI, and multivariate logistic regression was carried out to analyze the independent risk factors for VPI.

Kaplan--Meier method was adopted to generate survival curve, and log-rank test was performed to compare the differences of survival curves between patients' group. Cox regression model was used to assess the independent prognostic factors of VPI. Two-sided *P*-value \<0.05 was considered statistically significant. All analyses were performed with SPSS version 17.0 (SPSS Inc., Chicago, IL, USA).

Results
=======

Patients' characteristics
-------------------------

To investigate the association between clinicopathologic characteristics and *EGFR* mutations as well as VPI, 508 NSCLC patients who underwent primary tumor resection in one tertiary care hospital were included. The patients' characteristics are listed in [Table 1](#t1-cmar-11-1945){ref-type="table"}. The median age was 61 years old (range 25--91), and 293 patients (57.7%) were \>60 years when diagnosed. Male patients accounted for 52% of all cases. Sixty-one percent of patients were never smokers, and 39% of patients had a history of smoking. The mean tumor size was 27.3 mm, and most tumors were no more than 30 mm (70.1%), and only 7.1% of tumors were \>50 mm. 77.6% of tumors did not contain ground-glass opacity (GGO). According to eighth edition of pathological TNM stage, 67.5% of patients were in stage I, 10.6% of patients were in stage II, and 21.9% of patients were in stage III. Twenty-two percent of patients (intrapulmonary lymph node-N1 4.7%, and mediastinal lymph node-N2 17.9%) were detected lymphatic metastasis. 80.9% of patients were diagnosed as ADC, 16.1% of patients were SCC. Based on the CT image, five different types describing tumor--pleural relationship were presented: no contacting (28.9%), abutting pleural (32.1%), pleural tag type I (13.6%), pleural tag type II (19.5%), and pleural tag type III (5.9%; [Figure S1](#SD1-cmar-11-1945){ref-type="supplementary-material"}). According to pathological diagnosis, 45.1% of patients showed VPI. The results of *EGFR* mutation status showed that 19-del and L858R accounted for 19.5% and 24% of all the subtypes, respectively. 55.3% of patients received postoperative adjuvant therapy. The median follow-up time was 50 (range 3--57) months. The median DFS time was 49 (range 2--57) months.

Association between VPI and clinicopathologic characteristics
-------------------------------------------------------------

In order to investigate the potential correlation between VPI and clinicopathologic characteristics, the following data including age, gender, smoking status, tumor size, pTNM stage, histological type, tumor location, tumor--pleural relationship, lymphatic metastasis and preoperative CEA were collected to uncover the association between VPI and clinical factors. The results are listed in [Table 2](#t2-cmar-11-1945){ref-type="table"}.

The distribution of gender, smoking status, nodule type, histological type, preoperative CEA level, *EGFR* mutations, pTNM stage, lymphatic metastasis, and tumor--pleural relationship showed significant differences between VPI and non-VPI groups. Significant difference in tumor size was also observed in the two groups (*P*=0.022). The results of univariate logistic regression analysis showed that all positive characteristics presented in chi-squared test were significantly associated with the increased risk of VPI development (OR \>1.00, *P*\<0.05), except histological type; SCC could significantly reduce the risk of VPI occurrence (OR =0.18, 95%CI =0.10--0.33, *P*\<0.001) compared with ADC. After adjusting the covariates in multivariate logistic regression analysis, tumor size (OR =1.02, 95%CI =1.01--1.04, *P*=0.041), *EGFR* mutations (adjusted OR =2.13, 95%CI =1.13--3.99, *P*=0.019 for 19-del, and adjusted OR =2.89, 95%CI =1.58--5.29, *P*=0.001 for L858R compared to *EGFR* wild-type), and tumor--pleural relationship (adjusted OR =2.54, 95%CI =2.14--3.02, *P~trend~*\<0.001) showed independent risk factors for VPI. SCC was an independent protective factor for the development of VPI (adjusted OR =0.17, 95%CI =0.06--0.43, *P*\<0.001 compared with ADC).

Association between EGFR mutations and clinicopathologic characteristics
------------------------------------------------------------------------

To further investigate the distribution of *EGFR* mutations in VPI and non-VPI patients, chi-squared test and logistic regression analysis were carried out to analyze the association between clinicopathologic characteristics and *EGFR* mutations. The covariate factors including age, gender, smoking status, tumor size, nodule type, pTNM stage, histological type, tumor--pleural surface relationship, lymphatic metastasis, and preoperative CEA were collected in this study. The results showed that gender, smoking status, tumor size, nodule type, histological type, tumor--pleural relationship, and VPI presented significant association with *EGFR* mutations ([Table S1](#SD2-cmar-11-1945){ref-type="supplementary-material"}), including 19-del ([Table S2](#SD3-cmar-11-1945){ref-type="supplementary-material"}) and L858R ([Table S3](#SD4-cmar-11-1945){ref-type="supplementary-material"}).

The prevalence of *EGFR* mutations was 47.8% in NSCLC in this study. More female patients (61.7% vs 38.3%, *P*\<0.001) and never smokers (74.1% vs 25.9%, *P*\<0.001) harbored *EGFR* mutations. *EGFR*-mutant nodules tended to be much smaller (24.47±12.92 vs 29.90±16.23 mm, *P*\<0.001) and contained GGO component (*P*\<0.001; [Table S1](#SD2-cmar-11-1945){ref-type="supplementary-material"}). Compared with nodules containing GGO component, the mutation rate of *EGFR* was significantly decreased in solid tumors (OR =0.39, 95%CI =0.24--0.65, *P*\<0.001), and only L858R presented significant association with nodule type after adjusting covariates (adjusted OR =0.33, 95%CI =0.18--0.59, *P*\<0.001) in subgroup analysis ([Table 3](#t3-cmar-11-1945){ref-type="table"}). Analysis for histological type showed that 96.7% of *EGFR* mutations presented in ADC and the mutation rate of *EGFR* was 57.2% in ADC ([Table S1](#SD2-cmar-11-1945){ref-type="supplementary-material"}). Compared with ADC, the mutation rates of both 19-del (adjusted OR =0.05, 95%CI =0.01--0.41, *P*\<0.001) and L858R (adjusted OR =0.05, 95%CI =0.01--0.34, *P*=0.003) were significantly decreased in SCC ([Table 3](#t3-cmar-11-1945){ref-type="table"}). VPI also showed significant association with *EGFR* mutations (adjusted OR =2.21, 95%CI =1.36--3.59, *P*=0.001), and higher frequency of *EGFR* mutations occurred in tumors with VPI (adjusted OR =2.21, 95%CI =1.36--3.59, *P*=0.001). Subgroup analysis showed that only L858R showed significant association with VPI (adjusted OR =2.63, 95%CI =1.42--4.88, *P*=0.002), 19-del presented potential significance level of *P*\<0.05 with VPI (*P*=0.053). Lymphatic metastasis analysis showed that only 19-del was an independent risk factor for intrapulmonary lymph node (N1) metastasis (adjusted OR =5.02, 95%CI =1.59--15.81, *P*=0.006; [Table 3](#t3-cmar-11-1945){ref-type="table"}).

Disease-free survival analysis in non-VPI and VPI patients
----------------------------------------------------------

To investigate the association between survival and VPI as well as *EGFR* mutations, DFS analysis were carried out in this study. Survival curve analysis showed that VPI was significantly associated with DFS (log-rank *P*=0.047; [Figure 1A](#f1-cmar-11-1945){ref-type="fig"}). *EGFR* mutations presented better DFS compared with *EGFR* wild-type, but did not reach the significance level of 0.05 ([Figure 1B](#f1-cmar-11-1945){ref-type="fig"}). Subgroup analysis in VPI and non-VPI showed that whether 19-del or L858R was significantly associated with DFS (log-rank *P*=0.004 for 19-del, and log-rank *P*=0.024 for L858R, respectively; [Figure 1C](#f1-cmar-11-1945){ref-type="fig"}) in non-VPI group; however, no significant association was found between *EGFR* mutations and DFS (log-rank *P*\>0.05) in VPI group ([Figure 1D](#f1-cmar-11-1945){ref-type="fig"}). There was no significant difference between VPI and non-VPI in *EGFR* wild-type group ([Figure 1E](#f1-cmar-11-1945){ref-type="fig"}). Survival curve analysis in *EGFR* mutation groups showed that the significant difference between VPI and non-VPI was present only in 19-del group (log-rank *P*=0.002), but not in L858R (log-rank *P*=0.090; [Figure 1F](#f1-cmar-11-1945){ref-type="fig"}).

The Cox regression analysis showed that after adjusting the significant factors in univariate analysis, *EGFR* 19-del (adjusted HR =0.31, 95%CI =0.12--0.80, *P*=0.015) could significantly decrease the risk of DFS, and was the independent prognosis factor for DFS in non-VPI group; preoperative CEA level (adjusted HR =2.32, 95%CI =1.40--3.85, *P*=0.001) and lymphatic metastasis (adjusted HR =1.78, 95%CI =1.36--2.32, *P~trend~*\<0.001) were independent risk factors for DFS in non-VPI group. In VPI group, only lymphatic metastasis (adjusted HR =2.36, 95%CI =1.78--3.14, *P~trend~*\<0.001) was the independent risk factor for DFS ([Table 4](#t4-cmar-11-1945){ref-type="table"}).

Discussion
==========

*EGFR* is one of the most well-studied mutant genes in NSCLC. According to a recent meta-analysis, the average mutation rate of *EGFR* ranged from 9.6% to 82.2% worldwide, which was higher in Asian population than in other races on average (43.5% vs 37.9%).[@b19-cmar-11-1945] VPI was considered as an adverse prognostic factor in NSCLC; for this reason, tumors \<3 cm will be upstaged to T2 stage if they invade the visceral pleural according to the eighth edition of AJCC TNM classification for lung cancer.[@b13-cmar-11-1945] However, limited researches were focused on the association between *EGFR* mutations and VPI. In this retrospective study, 508 patients who underwent primary tumor lobectomy were enrolled to analyze the association between *EGFR* mutations and VPI as well as their roles in the prognosis of NSCLC patients. Our results showed that 47.8% NSCLC patients harbored *EGFR* mutations, among which 19-del and L858R are the two main subtypes. 45.1% of patients presented VPI. *EGFR* mutations were significantly associated with VPI, and higher frequency of *EGFR* mutations was found in VPI patients. Tumor--pleural relationship indicated to be an important CT feature as it showed great association with VPI. In 19-del group, VPI showed significant association with DFS and was identified to be an independent risk factor. At the same time, 19-del was found to have an important prognostic value for a better DFS in non-VPI patients. Lymphatic metastasis was an independent risk factor for DFS in both VPI and non-VPI patients.

Tumor that abuts the pleural surface does not necessarily mean pleural invasion. The possibility of VPI can be further predicted by 1) the obtuse angle between pleural surface and lesion; 2) contact length \>3 cm, and 3) thickening of adjacent pleural. The combination of all these image markers can reach a sensitivity of 87% and a specificity of 68%.[@b20-cmar-11-1945] Hsu et al[@b18-cmar-11-1945] first reported that for tumors that do not abut the pleural surface, pleural tags might be a sensitive predictor of VPI on CT image. The authors classified pleural tags into three types in their study, and showed that the pleural tag increased its accuracy of VPI invasion from the order of type I, type III, and type II, which was consistent with ours. Our study also showed that no VPI was diagnosed in the tumors without pleural contact on CT scans, and tumors abutted the pleural surface was an independent risk factor for the development of VPI.

The influence of VPI on the prognosis of resected NSCLC patients has not reached an agreement. Some previous studies revealed that VPI was recognized as an adverse independent factor for the prognosis in NSCLC patients who underwent tumor resection.[@b15-cmar-11-1945],[@b21-cmar-11-1945] David et al excluded the association between VPI and OS or DFS in tumors \<5 cm.[@b22-cmar-11-1945] Yanagawa et al found that VPI failed to be an independent predictor for decreased survival in resected stage I patient.[@b23-cmar-11-1945] In our study, we observed that VPI had an adverse effect on the DFS in NSCLC patients. Further stratified analysis in VPI and non-VPI subgroups identified that only regional lymph node metastasis actually decreased survival independently in VPI group. In non-VPI group, *EGFR* mutation was an independent factor for a better DFS.

Patients with *EGFR* mutation are recommended for TKIs target therapy; however, the prognostic value of *EGFR* mutations in resected NSCLC patients is still under debate. Kim et al suggested that *EGFR* mutation is not a prognostic factor for patients after tumor resection,[@b24-cmar-11-1945] whereas the research published by Takamochi et al[@b8-cmar-11-1945] demonstrated that *EGFR* mutations contributed to better DFS and OS. Lee et al[@b25-cmar-11-1945] retrospectively reviewed 117 patients who underwent curative resection and pointed out that *EGFR* mutations may benefit patients' DFS. D'Angelo et al[@b26-cmar-11-1945] studied 1,118 postoperative patients with stage I--III lung cancers and showed that *EGFR* mutations lowered death rate significantly. The underlying mechanism for this prognostic significance of *EGFR* mutations in NSCLC remains unclear. It is speculated that the progression of *EGFR*-mutated lung cancer cells was less likely to be interacted with other oncogenes, making the survival of these patients better than those who exhibit higher nonsynonymous mutation burden.[@b27-cmar-11-1945]

Exon 19 (19-del) and Exon 21 (L858R) account for \>80% of *EGFR* gene mutations. Li et al reported that mutation frequencies in exon 19 were significantly higher in early stage lung cancer (I/II), whereas L858R were more common in tumors having lymph node metastasis and late stage (III/IV).[@b28-cmar-11-1945] Renaud et al analyzed 108 19-del and 88 L858R surgically treated NSCLC patients and concluded that exon19 confers a better OS than exon 21 in stage II and III NSCLC.[@b7-cmar-11-1945] However, Takamochi et al compared the prognosis between L858R and 19-del in resected tumors, and no differences in OS and DFS were observed.[@b8-cmar-11-1945] Our data showed that both 19-del and L858R could significantly increase the DFS in non-VPI patients. However, after adjusting for covariates, only 19-del was identified as an independent prognostic factor for better DFS in non-VPI patients. No significant results were found in VPI group. It is possible that in VPI patients, the merit of *EGFR* mutations in improving DFS could be eliminated by strong invasive potential to visceral pleural; whereas, the favorable prognostic significance of *EGFR* mutations, especially 19-del, could be displayed in patients without VPI.

*EGFR* mutations occur more frequently in patients with malignant pleural effusion than those without,[@b29-cmar-11-1945] which may indicate that *EGFR* mutation is closely related to the invasiveness of NSCLC. To the best of our knowledge, few studies have analyzed the relationship between VPI and *EGFR* mutations. Le et al[@b30-cmar-11-1945] suggested that *EGFR* signaling pathway may promote the development of VPI through its downstream effector miR-135b. Hence, the clinical meaning of *EGFR* mutations correlated with VPI should be studied. Lin et al observed no association between *EGFR* mutations and visceral pleural surface invasion in 172 patients with tumors no more than 2 cm.[@b31-cmar-11-1945] In our study, we found that both 19-del and L858R were significantly associated with VPI as well as independent risk factors for VPI. Furthermore, we identified that the frequency of *EGFR* mutations was increased from the order of pleural tag type I, type III, and type II, which consisted with the predictive accuracy of VPI occurrence. This result infers that *EGFR* mutations might play important roles in the development of VPI. We also demonstrated that only 19-del was an independent factor for the increased DFS in non-VPI patient.

Our study also has several limitations. The data were based on a retrospective study in a single center, which may cause selection bias inevitably. We did not show the depth of VPI infiltration using elastic staining. VPI-positive patients in our study were defined as PL1 and PL2.[@b32-cmar-11-1945] Besides, we did not show the overall survival in this study. A variety of methods and therapeutic strategies after disease recurrence including chemotherapy, radiotherapy, target therapy, and palliative care were decided by patients, and we considered that this discrepancy may interfere with the overall survival.

Conclusion
==========

In this study, we identified that there was a significant association between *EGFR* mutations and VPI. *EGFR* mutations could significantly increase the risk of VPI, and higher frequency of L858R was detected in VPI patients. *EGFR* mutations might not benefit the survival of patients with VPI, but conversely 19-del was an independent favorable prognostic factor for DFS in patients without VPI.

Supplementary material
======================

###### 

Five types of tumor--pleural surface relationship.

**Notes:** (**A**) No contacting, (**B**) abutting pleural, (**C**) pleural tag type I, (**D**) pleural tag type II, and (**E**) pleural tag type III. The red arrows illustrate the five types of tumor--pleural surface relationship on CT images.

###### 

Association analysis between *EGFR* mutations and clinicopathologic characteristics

  Characteristics                                        Total                                              *EGFR* wild- type   *EGFR* mutant   χ^2^   *P*-value                                                  Univariate analysis                                   
  ------------------------------------------------------ -------------------------------------------------- ------------------- --------------- ------ ---------------------------------------------------------- --------------------- ----------- ------------------- -------------
                                                         508                                                265                 52.2            243    47.8                                                                                                             
  Age, years (mean ± SD)                                                                                    60.82±10.21         61.82±9.05             0.241[a](#tfn10-cmar-11-1945){ref-type="table-fn"}         1.01 (0.99--1.03)     0.243                           
   \<60                                                  215                                                120                 45.3            95     39.1                                                       1.99                  0.158                           
   ≥60                                                   293                                                145                 54.7            148    60.9                                                                                                             
  Gender                                                                                                                                                                                                          35.01                 \<0.001                         
   Male                                                  264                                                171                 64.5            93     38.3                                                                                         1.00 (reference)    
   Female                                                244                                                94                  35.5            150    61.7                                                                                         2.93 (2.05--4.21)   \<0.001
  Smoking status                                                                                                                                                                                                  33.36                 \<0.001                         
   Ever                                                  198                                                135                 50.9            63     25.9                                                                                         1.00 (reference)    
   Never                                                 310                                                130                 49.1            180    74.1                                                                                         2.97 (2.04--4.32)   \<0.001
  Tumor size, mm (mean ± SD)                                                                                29.90±16.23         24.47±12.92            \<0.001**[a](#tfn10-cmar-11-1945){ref-type="table-fn"}**   0.97 (0.96--0.99)     \<0.001                         
   ≤30                                                   356                                                164                 61.9            192    79                                                         18.36                 \<0.001     1.00 (reference)    
   30--50                                                116                                                75                  28.3            41     16.9                                                                                         0.47 (0.30--0.72)   0.001
   \>50                                                  36                                                 26                  9.8             10     4.1                                                                                          0.33 (0.15--0.70)   0.004
   Trend                                                                                                                                                                                                                                            0.52 (0.39--0.71)   \<0.001
  Nodule type                                                                                                                                                                                                     24.96                 \<0.001                         
   Non-solid                                             114                                                36                  13.6            78     32.1                                                                                         1.00 (reference)    
   Solid                                                 394                                                229                 86.4            165    67.9                                                                                         0.33 (0.21--0.52)   \<0.001
  pTNM stage                                                                                                                                                                                                      2.19                  0.335                           
   I                                                     343                                                173                 65.3            170    70                                                                                           1.00 (reference)    
   II                                                    54                                                 33                  12.5            21     8.6                                                                                          0.65 (0.36--1.16)   0.147
   III                                                   111                                                59                  22.3            52     21.4                                                                                         0.90 (0.58--1.38)   0.619
   Trend                                                                                                                                                                                                                                                                
  Histological type                                                                                                                                                                                               77.71                 \<0.001                         
   ADC                                                   411                                                176                 66.4            235    96.7                                                                                         1.00 (reference)    
   SCC                                                   82                                                 78                  29.4            4      1.6                                                                                          0.04 (0.01--0.11)   \<0.001
   Others[b](#tfn11-cmar-11-1945){ref-type="table-fn"}   15                                                 11                  4.2             4      1.6                                                                                          0.27 (0.09--0.87)   0.028
  VPI                                                                                                                                                                                                             25.81                 \<0.001                         
   No                                                    279                                                174                 65.7            105    43.2                                                                                         1.00 (reference)    
   Yes                                                   229                                                91                  34.3            138    56.8                                                                                         2.51 (1.76--3.60)   \<0.001
  Preoperative CEA (ng/mL)                               499[c](#tfn12-cmar-11-1945){ref-type="table-fn"}                                                                                                         1.47                  0.225                           
   \<5                                                   378                                                202                 78              176    73.3                                                                                         1.00 (reference)    
   ≥5                                                    121                                                57                  22              64     26.7                                                                                         1.29 (0.86--1.94)   0.226
  Lymphatic metastasis                                                                                                                                                                                            2.17                  0.338                           
   N0                                                    393                                                208                 78.5            185    76.1                                                                                         1.00 (reference)    
   N1                                                    24                                                 9                   3.4             15     6.2                                                                                          1.87 (0.80--4.38)   0.147
   N2                                                    91                                                 48                  18.1            43     17.7                                                                                         1.01 (0.64--1.59)   0.975
   Trend                                                                                                                                                                                                                                            1.03 (0.83--1.29)   0.778
  Tumor--pleural relationship                                                                                                                                                                                     15.62                 **0.004**                       
   No contacting                                         147                                                95                  35.8            52     21.4                                                                                         1.00 (reference)    
  Pleural tag type I                                     69                                                 33                  12.5            36     14.8                                                                                         1.99 (1.12--3.56)   **0.02**
   Pleural tag type II                                   99                                                 40                  15.1            59     24.3                                                                                         2.70 (1.59--4.56)   \<**0.001**
   Pleural tag type III                                  30                                                 14                  5.3             16     6.6                                                                                          2.09 (0.95--4.61)   0.069
   Abutting pleural                                      163                                                83                  31.3            80     32.9                                                                                         1.76 (1.12--2.78)   **0.015**
   Trend                                                                                                                                                                                                                                            1.13 (1.01--1.25)   **0.032**

**Notes:**

*P*-value for independent *t*-test.

Other histological types including large cell lung cancer and adenosquamous carcinoma.

A total of 499 patients underwent preoperative CEA examination in this study.

**Abbreviations:** ADC, adenocarcinoma; CEA, carcinoembryonic antigen; pTNM, pathological TNM; SCC, squamous cell carcinoma; VPI, visceral pleural invasion.

###### 

Association analysis between *EGFR* 19-del and clinicopathologic characteristics

  Characteristics                                        Total                                              *EGFR* wild-type   *EGFR* 19-del   *P*-value                                            Univariate analysis                                 
  ------------------------------------------------------ -------------------------------------------------- ------------------ --------------- ---------------------------------------------------- --------------------- --------- ------------------- ---------
                                                         508                                                265                52.2                                                                                                                     
  Age, years (mean ± SD)                                                                                    60.82±10.21        60.36±9.68      0.92[a](#tfn14-cmar-11-1945){ref-type="table-fn"}    0.99 (0.97--1.02)     0.703                         
   \<60                                                  215                                                120                45.3            43                                                   43.4                  0.752                         
   ≥60                                                   293                                                145                54.7            56                                                   56.6                                                
  Gender                                                                                                                                                                                                                  \<0.001                       
   Male                                                  264                                                171                64.5            35                                                   35.4                            1.00 (reference)    
   Female                                                244                                                94                 35.5            64                                                   64.6                            3.33 (2.05--5.39)   \<0.001
  Smoking status                                                                                                                                                                                                          \<0.001                       
   Ever                                                  198                                                135                50.9            26                                                   26.3                            1.00 (reference)    
   Never                                                 310                                                130                49.1            73                                                   73.7                            2.92 (1.75--4.85)   \<0.001
  Tumor size, mm (mean ± SD)                                                                                29.90±16.23        24.00±12.84     0.001[a](#tfn14-cmar-11-1945){ref-type="table-fn"}   0.97 (0.96--0.99)     0.002                         
   ≤30                                                   356                                                164                61.9            78                                                   78.8                  0.008     1.00 (reference)    
   30--50                                                116                                                75                 28.3            17                                                   17.2                            0.48 (0.26--0.86)   0.014
   \>50                                                  36                                                 26                 9.8             4                                                    4                               0.32 (0.11--0.96)   0.042
  Trend                                                                                                                                                                                                                             0.52 (0.34--0.81)   0.003
   Nodule type                                                                                                                                                                                                            0.001                         
   Non-solid                                             114                                                36                 13.6            28                                                   28.3                            1.00 (reference)    
   Solid                                                 394                                                229                86.4            71                                                   71.7                            0.40 (0.23--0.70)   0.001
  pTNM stage                                                                                                                                                                                                              0.933                         
   I                                                     343                                                173                65.3            65                                                   65.7                            1.00 (reference)    
   II                                                    54                                                 33                 12.5            11                                                   11.1                            0.89 (0.42--1.86)   0.751
   III                                                   111                                                59                 22.3            23                                                   23.2                            1.04 (0.59--1.82)   0.897
   Trend                                                                                                                                                                                                                            1.01 (0.77--1.33)   0.952
  Histological type                                                                                                                                                                                                       \<0.001                       
   ADC                                                   411                                                176                66.4            97                                                   98                              1.00 (reference)    
   SCC                                                   82                                                 78                 29.4            1                                                    1                               0.02 (0.01--0.17)   \<0.001
   Others[b](#tfn15-cmar-11-1945){ref-type="table-fn"}   15                                                 11                 4.2             1                                                    1                               0.17 (0.02--1.30)   0.087
  VPI                                                                                                                                                                                                                     \<0.001                       
   No                                                    279                                                174                65.7            41                                                   41.4                            1.00 (reference)    
   Yes                                                   229                                                91                 34.3            58                                                   58.6                            2.71 (1.69--4.34)   \<0.001
  Preoperative CEA (ng/mL)                               499[c](#tfn16-cmar-11-1945){ref-type="table-fn"}                                                                                                                 0.617                         
   \<5                                                   378                                                202                78              74                                                   75.5                            1.00 (reference)    
   ≥5                                                    121                                                57                 22              24                                                   24.5                            1.15 (0.67--1.99)   0.617
  Lymphatic metastasis                                                                                                                                                                                                    0.102                         
   N0                                                    393                                                208                78.5            73                                                   73.7                            1.00 (reference)    
   N1                                                    24                                                 9                  3.4             9                                                    9.1                             2.85 (1.09--7.45)   0.033
   N2                                                    91                                                 48                 18.1            17                                                   17.2                            1.01 (0.55--1.87)   0.977
   Trend                                                                                                                                                                                                                            1.07 (0.79--1.43)   0.676
  Tumor--pleural relationship                                                                                                                                                                                             0.018                         
   No contacting                                         147                                                95                 35.8            18                                                   18.2                            1.00 (reference)    
   Pleural tag type I                                    69                                                 33                 12.5            14                                                   14.1                            2.24 (1.01--5.00)   0.049
   Pleural tag type II                                   99                                                 40                 15.1            24                                                   24.2                            3.17 (1.55--6.47)   0.002
   Pleural tag type III                                  30                                                 14                 5.3             5                                                    5.1                             2.42 (1.28--4.55)   0.275
   Abutting pleural                                      163                                                83                 31.3            38                                                   38.4                            2.42 (1.28--4.55)   0.006
   Trend                                                                                                                                                                                                                            1.19 (1.03--1.37)   0.016

**Notes:**

*P*-value for independent *t*-test.

Other histological types including large cell lung cancer and adenosquamous carcinoma.

A total of 499 patients underwent preoperative CEA examination in this study.

**Abbreviations:** ADC , adenocarcinoma; CEA, carcinoembryonic antigen; pTNM, pathological TNM; SCC, squamous cell carcinoma; VPI, visceral pleural invasion.

###### 

Association analysis between *EGFR* L858R and clinicopathologic characteristics

  Characteristics                                        Total                                              *EGFR* wild-type   *EGFR* L858R   *P*-value                                              Univariate analysis                                 
  ------------------------------------------------------ -------------------------------------------------- ------------------ -------------- ------------------------------------------------------ --------------------- --------- ------------------- ---------
                                                         508                                                265                52.2                                                                                                                      
  Age, years (mean ± SD)                                                                                    60.82±10.21        62.58±8.47     0.177[a](#tfn18-cmar-11-1945){ref-type="table-fn"}     1.02 (0.99--1.04)     0.097                         
   \<60                                                  215                                                120                45.3           44                                                     36.1                  0.088                         
   ≥60                                                   293                                                145                54.7           78                                                     63.9                                                
  Gender                                                                                                                                                                                                                   \<0.001                       
   Male                                                  264                                                171                64.5           45                                                     36.9                            1.00 (reference)    
   Female                                                244                                                94                 35.5           77                                                     63.1                            3.11 (1.99--4.86)   \<0.001
  Smoking status                                                                                                                                                                                                           \<0.001                       
   Ever                                                  198                                                135                50.9           30                                                     24.6                            1.00 (reference)    
   Never                                                 310                                                130                49.1           92                                                     75.4                            3.19 (1.98--5.13)   \<0.001
  Tumor size, mm (mean ± SD)                                                                                29.90±16.23        23.99±12.62    \<0.001[a](#tfn18-cmar-11-1945){ref-type="table-fn"}   0.97 (0.96--0.99)     0.001                         
   ≤30                                                   356                                                164                61.9           100                                                    82                    \<0.001   1.00 (reference)    
   30--50                                                116                                                75                 28.3           19                                                     15.6                            0.42 (0.24--0.73)   0.002
   \>50                                                  36                                                 26                 9.8            3                                                      2.5                             0.19 (0.06--0.64)   0.008
   Trend                                                                                                                                                                                                                             0.42 (0.28--0.66)   \<0.001
  Nodule type                                                                                                                                                                                                              \<0.001                       
   Non-solid                                             114                                                36                 13.6           44                                                     36.1                            1.00 (reference)    
   Solid                                                 394                                                229                86.4           78                                                     63.9                            0.28 (0.17--0.46)   \<0.001
  pTNM stage                                                                                                                                                                                                               0.06                          
   I                                                     343                                                173                65.3           90                                                     73.8                            1.00 (reference)    
   II                                                    54                                                 33                 12.5           6                                                      4.9                             0.35 (0.14--0.87)   0.023
   III                                                   111                                                59                 22.3           26                                                     21.3                            0.85 (0.50--1.44)   0.537
   Trend                                                                                                                                                                                                                             0.87 (0.67--1.13)   0.299
  Histological type                                                                                                                                                                                                        \<0.001                       
   ADC                                                   411                                                176                66.4           118                                                    96.7                            1.00 (reference)    
   SCC                                                   82                                                 78                 29.4           1                                                      0.8                             0.02 (0.01--0.14)   \<0.001
   Others[b](#tfn19-cmar-11-1945){ref-type="table-fn"}   15                                                 11                 4.2            3                                                      2.5                             0.41 (0.11--1.49)   0.174
  VPI                                                                                                                                                                                                                      \<0.001                       
   No                                                    279                                                174                65.7           54                                                     44.3                            1.00 (reference)    
   Yes                                                   229                                                91                 34.3           68                                                     55.7                            2.41 (1.55--3.73)   \<0.001
  Preoperative CEA (ng/mL)                               499[c](#tfn20-cmar-11-1945){ref-type="table-fn"}                                                                                                                  0.341                         
   \<5                                                   378                                                202                78             89                                                     73.6                            1.00 (reference)    
   ≥5                                                    121                                                57                 22             32                                                     26.4                            1.27 (0.77--2.10)   0.342
  Lymphatic metastasis                                                                                                                                                                                                     0.902                         
   N0                                                    393                                                208                78.5           94                                                     77                              1.00 (reference)    
   N1                                                    24                                                 9                  3.4            5                                                      4.1                             1.23 (0.40--3.77)   0.718
   N2                                                    91                                                 48                 18.1           23                                                     18.9                            1.06 (0.61--1.84)   0.836
   Trend                                                                                                                                                                                                                             1.04 (0.79--1.36)   0.789
  Tumor--pleural relationship                                                                                                                                                                                              0.054                         
   No contacting                                         147                                                95                 35.8           28                                                     23                              1.00 (reference)    
   Pleural tag type I                                    69                                                 33                 12.5           21                                                     17.2                            2.16 (1.08--4.31)   0.029
   Pleural tag type II                                   99                                                 40                 15.1           29                                                     23.8                            2.46 (1.30--4.65)   0.006
   Pleural tag type III                                  30                                                 14                 5.3            7                                                      5.7                             1.51 (0.85--2.68)   0.3
   Abutting pleural                                      163                                                83                 31.3           37                                                     30.3                            1.51 (0.85--2.68)   0.157
   Trend                                                                                                                                                                                                                             1.08 (0.94--1.23)   0.278

**Notes:**

*P*-value for independent *t*-test.

Other histological types including large cell lung cancer and adenosquamous carcinoma.

A total of 499 patients underwent preoperative CEA examination in this study.

**Abbreviations:** ADC, adenocarcinoma; CEA, carcinoembryonic antigen; pTNM, pathological TNM; SCC, squamous cell carcinoma; VPI, visceral pleural invasion.
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![DFS curve analysis for postoperative patients based on VPI and EGFR mutations.\
**Notes:** (**A**) DFS curves in VPI and non-VPI groups. (**B**) DFS curves in EGFR wild-type and EGFR mutation groups. (**C**) DFS curves in non-VPI patients stratified by EGFR mutations. (**D**) DFS curves in VPI patients stratified by EGFR mutations. (**E**) DFS curves in EGFR wild-type patients stratified by VPI. (**F**) DFS curves in EGFR mutation patients stratified by VPI.\
**Abbreviations:** DFS, disease-free survival; VPI, visceral pleural invasion.](cmar-11-1945Fig1){#f1-cmar-11-1945}

###### 

Clinicopathologic characteristics and prognosis of patients

  Patient characteristics                               Total                                             Number        \%
  ----------------------------------------------------- ------------------------------------------------- ------------- ------
  Total patients                                        508                                                             
  Age, years (median, range)                            508                                               61 (25--91)   
   \<60                                                                                                   215           42.3
   ≥60                                                                                                    293           57.7
  Gender                                                508                                                             
   Male                                                                                                   264           52
   Female                                                                                                 244           48
  Smoking status                                        508                                                             
   Ever                                                                                                   198           39
   Never                                                                                                  310           61
  Tumor size, mm (mean ± SD)                            508                                               27.3±14.97    
   ≤30                                                                                                    356           70.1
   30--50                                                                                                 116           22.8
   \>50                                                                                                   36            7.1
  Nodule type                                           508                                                             
   Non-solid                                                                                              114           22.4
   Solid                                                                                                  394           77.6
  pTNM stage (eighth edition)                           508                                                             
   I                                                                                                      343           67.5
   II                                                                                                     54            10.6
   III                                                                                                    111           21.9
  Lymphatic metastasis                                  508                                                             
   N0                                                                                                     393           77.4
   N1                                                                                                     24            4.7
   N2                                                                                                     91            17.9
  Histological type                                     508                                                             
   ADC                                                                                                    411           80.9
   SCC                                                                                                    82            16.1
   Others[a](#tfn1-cmar-11-1945){ref-type="table-fn"}                                                     15            3
  VPI                                                   508                                                             
   Yes                                                                                                    229           45.1
   No                                                                                                     279           54.9
  Tumor--pleural relationship                           508                                                             
   No contacting                                                                                          147           28.9
   Pleural tag type I                                                                                     69            13.6
   Pleural tag type II                                                                                    99            19.5
   Pleural tag type III                                                                                   30            5.9
   Abutting pleural                                                                                       163           32.1
  *EGFR* mutation status                                508                                                             
   Wild-type                                                                                              265           52.2
   19-del                                                                                                 99            19.5
   L858R                                                                                                  122           24
   Others[b](#tfn2-cmar-11-1945){ref-type="table-fn"}                                                     22            19.1
  Preoperative CEA (ng/mL)                              499[c](#tfn3-cmar-11-1945){ref-type="table-fn"}                 
   \<5                                                                                                    378           75.8
   ≥5                                                                                                     121           24.2
  Postoperative therapy                                 508                                                             
   No                                                                                                     227           44.7
   Yes                                                                                                    281           55.3
  Follow-up time, months (median, range)                                                                  50 (3--57)    
  DFS, months (median, range)                                                                             49 (2--57)    

**Notes:**

Other histological types include large cell lung cancer and adenosquamous carcinoma.

Other mutation types include 20-ins, G719X, T790M, and L861Q.

A total of 499 patients underwent preoperative CEA examination in this study.

**Abbreviations:** ADC, adenocarcinoma; CEA, carcinoembryonic antigen; DFS, disease-free survival; pTNM, pathological TNM; SCC, squamous cell carcinoma; VPI, visceral pleural invasion.

###### 

Association analysis between clinicopathologic characteristics and VPI

  Characteristics               Total                                             VPI(--)       VPI(+)        *P*-value for χ^2^                                  Univariate analysis   Multivariate analysis                        
  ----------------------------- ------------------------------------------------- ------------- ------------- --------------------------------------------------- --------------------- ----------------------- -------------------- ---------
                                508                                               279 (54.9)    229 (45.1)                                                                                                                           
  Gender                                                                                                      \<0.001                                                                                                                
   Male                         264                                               165 (59.1)    99 (42.1)                                                         1.00 (reference)                              1.00 (reference)     
   Female                       244                                               114 (40.9)    130 (56.8)                                                        1.90 (1.33--2.71)     \<0.001                 1.66 (0.88--3.12)    0.119
  Smoking status                                                                                              \<0.001                                                                                                                
   Ever                         198                                               131 (47.0)    67 (29.3)                                                         1.00 (reference)                              1.00 (reference)     
   Never                        310                                               148 (53.0)    162 (70.7)                                                        2.14 (1.48--3.10)     \<0.001                 1.29 (0.68--2.44)    0.430
  Tumor size, mm (mean ± SD)                                                      25.92±14.73   28.98±15.13   0.022[a](#tfn5-cmar-11-1945){ref-type="table-fn"}   1.01 (1.00--1.03)     0.023                   1.02 (1.01--1.04)    0.041
  Nodule type                                                                                                 0.015                                                                                                                  
   Non-solid                    114                                               74 (26.5)     40 (17.5)                                                         1.00 (reference)                              1.00 (reference)     
   Solid                        394                                               205 (73.5)    189 (82.5)                                                        1.71 (1.11--2.63)     0.016                   1.48 (0.81--2.72)    0.205
  Histological type                                                                                           \<0.001                                                                                                                
   ADC                          411                                               200 (71.7)    211 (92.1)                                                        1.00 (reference)                              1.00 (reference)     
   SCC                          82                                                69 (24.7)     13 (5.7)                                                          0.18 (0.10--0.33)     \<0.001                 0.17 (0.06--0.43)    \<0.001
  Preoperative CEA (ng/mL)      499[b](#tfn6-cmar-11-1945){ref-type="table-fn"}                               0.042                                                                                                                  
   \<5                          378                                               218 (79.3)    160 (71.4)                                                        1.00 (reference)                              1.00 (reference)     
   ≥5                           121                                               57 (20.7)     64 (28.6)                                                         1.53 (1.01--2.31)     0.043                   0.88 (0.51--1.54)    0.660
  *EGFR* mutation status                                                                                      \<0.001                                                                                                                
   Wild-type                    265                                               174 (62.4)    91 (39.7)                                                         1.00 (reference)                              1.00 (reference)     
   19-del                       99                                                41 (14.7)     58 (25.3)                                                         2.71 (1.69--4.34)     \<0.001                 2.13 (1.13--3.99)    0.019
   L858R                        122                                               54 (19.4)     68 (29.7)                                                         2.41 (1.55--3.73)     \<0.001                 2.89 (1.58--5.29)    0.001
  Tumor--pleural relationship                                                                                 \<0.001                                                                                                                
   No contacting                147                                               147 (52.7)    0 (0.0)                                                           /                     /                       /                    /
   Pleural tag type I           69                                                43 (15.4)     26 (11.4)                                                         1.00 (reference)                              1.00 (reference)     
   Pleural tag type II          99                                                33 (15.4)     66 (28.8)                                                         3.31 (1.74--6.28)     \<0.001                 4.19 (2.03--8.65)    \<0.001
   Pleural tag type III         30                                                12 (4.3)      18 (7.9)                                                          2.48 (1.03--5.97)     0.043                   2.54 (0.98--6.55)    0.054
   Abutting pleural             163                                               44 (15.8)     119 (52.0)                                                        4.47 (2.46--8.13)     \<0.001                 6.52 (3.26--13.05)   \<0.001
  Trend                                                                                                                                                           2.35 (2.03--2.72)     \<0.001                 2.54 (2.14--3.02)    \<0.001
  Lymphatic metastasis                                                                                        0.005                                                                                                                  
   N0                           393                                               231 (82.8)    162 (70.7)                                                        1.00 (reference)                              1.00 (reference)     
   N1                           24                                                8 (3.2)       15 (6.6)                                                          2.38 (1.02--5.56)     0.046                   1.25 (0.38--4.10)    0.719
   N2                           91                                                39 (14.0)     52 (22.7)                                                         1.90 (1.20--3.02)     0.006                   0.55 (0.16--1.94)    0.354

**Notes:**

*P*-value for independent *t*-test.

A total of 499 patients underwent preoperative CEA examination in this study.

**Abbreviations:** ADC, adenocarcinoma; CEA, carcinoembryonic antigen; SCC, squamous cell carcinoma; VPI, visceral pleural invasion.

###### 

Multivariate logistic regression analysis between *EGFR* mutations and clinicopathologic characteristics

  Characteristics        *EGFR* mutations    *EGFR* 19-del   *EGFR* L858R                                     
  ---------------------- ------------------- --------------- -------------------- ------- ------------------- ---------
  Nodule type                                                                                                 
   Non-solid             1.00 (reference)                    1.00 (reference)             1.00 (reference)    
   Solid                 0.39 (0.24--0.65)   \<0.001         0.56 (0.29--1.07)    0.080   0.33 (0.18--0.59)   \<0.001
  Histological type                                                                                           
   ADC                   1.00 (reference)                    1.00 (reference)             1.00 (reference)    
   SCC                   0.08 (0.03--0.24)   \<0.001         0.05 (0.01--0.41)    0.005   0.05 (0.01--0.34)   0.003
  VPI                                                                                                         
   No                    1.00 (reference)                    1.00 (reference)             1.00 (reference)    
   Yes                   2.21 (1.36--3.59)   0.001           1.83 (0.99--3.37)    0.053   2.63 (1.42--4.88)   0.002
  Lymphatic metastasis                                                                                        
   N0                    /                                   1.00 (reference)             /                   
   N1                    /                   /               5.02 (1.59--15.81)   0.006   /                   /
   N2                    /                   /               1.34 (0.66--2.84)    0.393   /                   /
  Trend                  /                   /               1.24 (0.87--1.77)    0.225   /                   /

**Abbreviations:** ADC, adenocarcinoma; SCC, squamous cell carcinoma; VPI, visceral pleural invasion.

###### 

DFS analysis in non-VPI and VPI groups

  Variables                  Non-VPI             VPI                                                                                        
  -------------------------- ------------------- --------- ------------------- --------- -------------------- --------- ------------------- ---------
  Gender                                                                                                                                    
   Male                      1.00 (reference)              1.00 (reference)              1.00 (reference)               1.00 (reference)    
   Female                    0.47 (0.29--0.77)   0.003     0.80 (0.45--1.41)   0.440     0.56 (0.36--0.86)    0.007     0.71 (0.45--1.13)   0.150
  Tumor size (mm)                                                                                                                           
   ≤30                       1.00 (reference)              1.00 (reference)              1.00 (reference)               1.00 (reference)    
   30--50                    2.61 (1.63--4.16)   \<0.001   1.40 (0.81--2.44)   0.230     1.95 (1.21--3.13)    0.006     0.92 (0.54--1.56)   0.742
   \>50                      2.67 (1.26--5.66)   0.011     1.32 (0.57--3.05)   0.513     3.77 (1.99--7.14)    \<0.001   1.92 (0.94--3.94)   0.075
  Trend                      1.87 (1.39--2.53)   \<0.001   1.21 (0.83--1.76)   0.316     1.94 (1.45--2.61)    \<0.001   1.25 (0.87--1.80)   0.237
  Nodule type                                                                                                                               
   Non-solid                 1.00 (reference)              1.00 (reference)              1.00 (reference)               1.00 (reference)    
   Solid                     3.97 (1.91--8.24)   \<0.001   2.05 (0.91--4.60)   0.083     5.33 (1.95--14.55)   0.001     2.31 (0.80--6.66)   0.121
  Histological type                                                                                                                         
   ADC                       1.00 (reference)              1.00 (reference)              1.00 (reference)                                   
   SCC                       2.17 (1.38--3.41)   0.001     1.58 (0.87--2.86)   0.131     1.28 (0.56--2.93)    0.564                         
  Preoperative CEA (ng/mL)                                                                                                                  
   \<5                       1.00 (reference)              1.00 (reference)              1.00 (reference)               1.00 (reference)    
   ≥5                        2.55 (1.62--4.02)   \<0.001   2.32 (1.40--3.85)   0.001     2.10 (1.36--3.23)    0.001     1.10 (0.69--1.77)   0.688
  Lymphatic metastasis                                                                                                                      
   N0                        1.00 (reference)              1.00 (reference)              1.00 (reference)               1.00 (reference)    
   N1                        0.96 (0.23--3.95)   0.956     0.57 (0.14--2.38)   0.437     5.24 (2.58--10.67)   \<0.001   3.37 (1.56--7.28)   0.002
   N2                        5.27 (3.32--8.36)   \<0.001   3.24 (1.93--5.43)   \<0.001   6.73 (4.60--11.69)   \<0.001   5.48 (3.08--9.74)   \<0.001
  Trend                      2.27 (1.80--2.87)   \<0.001   1.78 (1.36--2.32)   \<0.001   2.69 (2.14--3.37)    \<0.001   2.36 (1.78--3.14)   \<0.001
  *EGFR* mutation status                                                                                                                    
   Wild-type                 1.00 (reference)              1.00 (reference)              1.00 (reference)               /                   
   19-del                    0.29 (0.12--0.71)   0.007     0.31 (0.12--0.80)   0.015     1.17 (0.69--1.97)    0.565     /                   /
   L858R                     0.49 (0.26--0.92)   0.028     0.96 (0.47--1.94)   0.899     0.88 (0.51--1.50)    0.631     /                   /
  Postoperative therapy                                                                                                                     
   No                        1.00 (reference)                                            1.00 (reference)                                   
   Yes                       2.91 (1.85--4.58)   \<0.001   1.40 (0.81--2.40)   0.225     2.07 (1.20--3.56)    0.009     0.89 (0.48--1.65)   0.720

**Abbreviations:** ADC, adenocarcinoma; CEA, carcinoembryonic antigen; DFS, disease-free survival; SCC, squamous cell carcinoma; VPI, visceral pleural invasion.
